NASDAQ:KIDS

OrthoPediatrics Stock Forecast, Price & News

$51.30
-0.37 (-0.72 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$50.49
Now: $51.30
$52.24
50-Day Range
$44.26
MA: $49.23
$55.80
52-Week Range
$38.01
Now: $51.30
$57.42
Volume70,103 shs
Average Volume200,674 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.67
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
OrthoPediatrics logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KIDS
CUSIPN/A
Phone574-268-6379
Employees116
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$72.55 million
Book Value$8.51 per share

Profitability

Net Income$-13,730,000.00

Miscellaneous

Market Cap$1.01 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableNot Optionable

Headlines

OrthoPediatrics (NASDAQ:KIDS) Shares Gap Up to $48.41
April 8, 2021 |  americanbankingnews.com
OrthoPediatrics (NASDAQ:KIDS) Stock Price Up 6.1%
April 6, 2021 |  americanbankingnews.com
OrthoPediatrics: Q4 Earnings Snapshot - Yahoo Finance
March 12, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.26 out of 5 stars

Medical Sector

867th out of 2,024 stocks

Surgical & Medical Instruments Industry

87th out of 169 stocks

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$51.30
-0.37 (-0.72 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KIDS News and Ratings via Email

Sign-up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OrthoPediatrics (NASDAQ:KIDS) Frequently Asked Questions

Is OrthoPediatrics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OrthoPediatrics stock.
View analyst ratings for OrthoPediatrics
or view top-rated stocks.

What stocks does MarketBeat like better than OrthoPediatrics?

Wall Street analysts have given OrthoPediatrics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OrthoPediatrics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OrthoPediatrics' next earnings date?

OrthoPediatrics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for OrthoPediatrics
.

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) posted its quarterly earnings results on Thursday, March, 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.46. OrthoPediatrics had a negative net margin of 34.26% and a negative trailing twelve-month return on equity of 11.57%.
View OrthoPediatrics' earnings history
.

How has OrthoPediatrics' stock price been impacted by Coronavirus (COVID-19)?

OrthoPediatrics' stock was trading at $39.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, KIDS shares have increased by 29.1% and is now trading at $51.30.
View which stocks have been most impacted by COVID-19
.

What guidance has OrthoPediatrics issued on next quarter's earnings?

OrthoPediatrics issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, March, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $93-98 million, compared to the consensus revenue estimate of $97.62 million.

What price target have analysts set for KIDS?

3 brokers have issued 12 month price targets for OrthoPediatrics' stock. Their forecasts range from $48.00 to $62.00. On average, they anticipate OrthoPediatrics' stock price to reach $55.80 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price.
View analysts' price targets for OrthoPediatrics
or view top-rated stocks among Wall Street analysts.

Who are OrthoPediatrics' key executives?

OrthoPediatrics' management team includes the following people:
  • Mr. Mark C. Throdahl, CEO & Director (Age 70, Pay $604.5k)
  • Mr. David R. Bailey, Pres (Age 42, Pay $444.36k)
  • Mr. Fred L. Hite, CFO, Principal Financial & Accounting Officer, COO and Director (Age 53, Pay $532.21k)
  • Mr. Daniel J. Gerritzen, VP of Legal & HR, Gen. Counsel and Sec. (Age 51, Pay $426k)
  • Mr. Gregory A. Odle, Exec. VP of Commercialization (Age 51, Pay $444.91k)
  • Mr. Joel Batts, Sr. VP of Science & Technology
  • Dr. Peter F. Armstrong M.D., Chief Medical Officer & Chair of Surgeon Advisory Board (Age 74)
  • Mr. Joe Hauser, Sr. VP & GM of Trauma & Deformity Correction
  • Mr. Mark Karshner, Sr. VP of International Sales

What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?

15 employees have rated OrthoPediatrics CEO Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among OrthoPediatrics' employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of OrthoPediatrics' key competitors?

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), The Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

When did OrthoPediatrics IPO?

(KIDS) raised $52 million in an IPO on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

What is OrthoPediatrics' stock symbol?

OrthoPediatrics trades on the NASDAQ under the ticker symbol "KIDS."

Who are OrthoPediatrics' major shareholders?

OrthoPediatrics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FDx Advisors Inc. (0.04%). Company insiders that own OrthoPediatrics stock include Bernie B Berry III, Daniel J Gerritzen, David R Bailey, David R Pelizzon, Fred Hite, Gregory A Odle, Mark C Throdahl and Stephen F Burns.
View institutional ownership trends for OrthoPediatrics
.

Which institutional investors are buying OrthoPediatrics stock?

KIDS stock was purchased by a variety of institutional investors in the last quarter, including FDx Advisors Inc..
View insider buying and selling activity for OrthoPediatrics
or or view top insider-buying stocks.

How do I buy shares of OrthoPediatrics?

Shares of KIDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrthoPediatrics' stock price today?

One share of KIDS stock can currently be purchased for approximately $51.30.

How much money does OrthoPediatrics make?

OrthoPediatrics has a market capitalization of $1.01 billion and generates $72.55 million in revenue each year. The company earns $-13,730,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

How many employees does OrthoPediatrics have?

OrthoPediatrics employs 116 workers across the globe.

What is OrthoPediatrics' official website?

The official website for OrthoPediatrics is www.orthopediatrics.com.

Where are OrthoPediatrics' headquarters?

OrthoPediatrics is headquartered at 2850 Frontier Drive, Warsaw IN, 46582.

How can I contact OrthoPediatrics?

OrthoPediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company can be reached via phone at 574-268-6379 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.